Details

Autor(en) / Beteiligte

• Paillassa, Jerome
• Cornet, Edouard
• Noel, Stephanie
• Tomowiak, Cecile
• Lepretre, Stephane
• Vaudaux, Sandrine
• Dupuis, Jehan
• Devidas, Alain
• Joly, Bertrand
• Petitdidier-Lionnet, Charlotte
• Haiat, Stephanie
• Mariette, Clara
• Thieblemont, Catherine
• Decaudin, Didier
• Validire-Charpy, Patricia
• Drenou, Bernard
• Eisenmann, Jean-Claude
• Uribe, Mario Ojeda
• Olivrie, Agnès
• Touati, Mohamed
• Lambotte, Olivier
• Hermine, Olivier
• Karsenti, Jean-Michel
• Feugier, Pierre
• Vaillant, Willy
• Gutnecht, Jean
• Lippert, Eric
• Huysman, Fabienne
• Ghomari, Kamel
• Boubaya, Marouane
• Levy, Vincent
• Riou, Jeremie
• Damaj, Gandhi
• Tanguy-Schmidt, Aline
• Hunault-Berger, Mathilde
• Troussard, Xavier

Titel

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up

Ist Teil von

• Blood cancer journal (New York), 2020-05, Vol.10 (5), p.62-62, Article 62

Ort / Verlag

United States: Springer Nature B.V

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In total, 279 patients with hairy-cell leukemia (HCL) were analyzed, with a median follow-up of 10 years. Data were collected up to June 2018. We analyzed responses to treatment, relapses, survival, and the occurrence of second malignancies during follow-up. The median age was 59 years. In total, 208 patients (75%) were treated with purine analogs (PNAs), either cladribine (159) or pentosatin (49), as the first-line therapy. After a median follow-up of 127 months, the median overall survival was 27 years, and the median relapse-free survival (RFS) was 11 years. The cumulative 10-year relapse incidence was 39%. In patients receiving second-line therapy, the median RFS was 7 years. For the second-line therapy, using the same or another PNA was equivalent. We identified 68 second malignancies in 59 patients: 49 solid cancers and 19 hematological malignancies. The 10-year cumulative incidences of cancers, solid tumors, and hematological malignancies were 15%, 11%, and 5.0%, respectively, and the standardized incidence ratios were 2.22, 1.81, and 6.67, respectively. In multivariate analysis, PNA was not a risk factor for second malignancies. HCL patients have a good long-term prognosis. PNAs are the first-line treatment. HCL patients require long-term follow-up because of their relatively increased risk of second malignancies.